Matsushima M, Kuwabara T, Miyamae K, Hachiya A, Kawahara M, Fukasawa K, Yagishita T, Tajima M, Sawamura Y, Shirai M
Hinyokika Kiyo. 1984 Jul;30(7):869-75.
We measured the serum TPA level in 260 patients with benign urogenital diseases, 189 patients with urogenital cancer and 72 healthy blood donors by using a radio-immunoassay kit in order to evaluate its usefulness as an indicator for the presence of cancer. TPA value (mean +/- 2SD) in healthy blood donors was in the range of 36.8-110.8 units per liter, so that values higher than 110 U/L were considered to be abnormal. Significantly higher serum TPA levels were observed in patients with non-treated cancers, compared to healthy blood donors. But elevated serum TPA levels were also observed in the patients with benign diseases, especially in cases of benign prostatic hyperplasia with urinary tract infection. Consequently, it is considered that the serum TPA test is very useful for detecting urogenital diseases, but not for screening urogenital cancer. In cases of urogenital cancer, serum TPA levels elevated significantly by recurrence or recrudescence of the disease. Therefore, a good correlation was established between serum TPA and the efficiency of a given therapy in patients with prostatic cancer and bladder cancer.
我们使用放射免疫分析试剂盒对260例良性泌尿生殖系统疾病患者、189例泌尿生殖系统癌症患者及72名健康献血者的血清组织多肽抗原(TPA)水平进行了检测,以评估其作为癌症存在指标的有效性。健康献血者的TPA值(均值±2标准差)在每升36.8 - 110.8单位范围内,因此高于110 U/L的值被认为异常。与健康献血者相比,未治疗癌症患者的血清TPA水平显著更高。但良性疾病患者中也观察到血清TPA水平升高,尤其是伴有尿路感染的良性前列腺增生病例。因此,认为血清TPA检测对检测泌尿生殖系统疾病非常有用,但对筛查泌尿生殖系统癌症无用。在泌尿生殖系统癌症病例中,血清TPA水平因疾病复发或再发而显著升高。因此,在前列腺癌和膀胱癌患者中,血清TPA与特定治疗效果之间建立了良好的相关性。